Name,Category,Begin Date,End Date,Note
Incidental Liver Lesion,Milestones,2022-09-01,,Found on screening ultrasound
CT and MRI Liver,Biomarker Assess,2022-09-10,,3.5cm intrahepatic mass
Liver Biopsy,Biomarker Assess,2022-09-18,,Intrahepatic cholangiocarcinoma
CA 19-9 Baseline,Biomarker Assess,2022-09-22,,320 U/mL
Comprehensive Genomic Profiling,Biomarker Assess,2022-09-25,,Sent to Foundation Medicine
PET-CT Staging,Biomarker Assess,2022-10-01,,Liver only no distant mets
Molecular Results,Biomarker Assess,2022-10-10,,FGFR2-BICC1 fusion detected
Tumor Board,Milestones,2022-10-15,,Borderline resectable
GemCis Cycle 1,Line 1 treatment,2022-10-24,2023-01-16,First-line standard chemotherapy
GemCis Cycles 2-4,Line 1 treatment,2022-11-14,2023-01-16,Completing 4 cycles
Restaging Shows Growth,Biomarker Assess,2023-01-23,,Progressive disease on chemo
Disease Progression,Complications,2023-01-23,,Failed first-line therapy
Pemigatinib Started,Line 2 treatment,2023-02-06,2023-08-15,FGFR inhibitor Pemazyre
Hyperphosphatemia Management,Complications,2023-03-01,,Diet modification and binders
6-Week Response Scan,Biomarker Assess,2023-03-20,,Partial response 42% shrinkage
CA 19-9 Dropping,Biomarker Assess,2023-03-20,,Down to 85 U/mL
3-Month Scan,Biomarker Assess,2023-05-06,,Continued response
6-Month Scan,Biomarker Assess,2023-08-06,,Stable near-complete response
Pemigatinib Resistance,Complications,2023-08-20,,New lesions appearing
Futibatinib 3L,Line 3 treatment,2023-09-05,2024-02-10,Second-generation FGFR inhibitor
Restaging Mixed Response,Biomarker Assess,2023-12-05,,Some lesions responding
